Balancing the benefits and harms of thyroid cancer surveillance in survivors of Childhood, adolescent and young adult cancer: Recommendations from the international Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCareSurFup Consortium

Clément, Sarah; Kremer, Leontien C. M.; Verburg, F. A.; Simmons, Jill H.; Goldfarb, Melanie; Peeters, Robin P.; Alexander, Erik K.; Bárdi, Edit; Brignardello, Enrico; Constine, Louis S.; Dinauer, Catherine; Дрозд, Валентина; Felicetti, Francesco; Frey, Eva; Heinzel, Alexander; Heuvel‐Eibrink, Marry M. van den; Huang, Stephen A.; Links, Thera P.; Lorenz, Kerstin; Mulder, Renée L.; Neggers, Sebastian J C M M; Dijkum, E. J. M. Nieveen van; Oeffinger, Kevin C.; Rijn, Rick R. van; Rivkees, Scott A.; Ronckers, Cécile M.; Schneider, Arthur B.; Skinner, Rod; Wasserman, Jonathan D.; Wynn, Tung; Hudson, Melissa M.; Nathan, Paul C.; Santen, Hanneke M van

doi:10.1016/j.ctrv.2017.11.005

Cited by 107 publications

(89 citation statements)

References 84 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An international multidisciplinary panel was recently convened in an attempt to harmonize screening practices, and the controversies surrounding this issue are nicely reviewed in that paper [125]. Based on the underlying evidence as well as the potential benefit gained by early detection and appropriate management, the panel concluded that neither thyroid ultrasound nor neck palpation was superior.…”

Section: Screening and Managementmentioning

confidence: 99%

“…All stakeholders agree that an annual physical examination of the thyroid gland and cervical lymph nodes serves as a foundation for thyroid cancer screening [125]. If a palpable abnormality is identified, a cervical ultrasound should be ordered and the ensuing evaluation and treatment of both benign and malignant disease would be similar to that of the general population [126].…”

Section: Screening and Managementmentioning

confidence: 99%

“…1), it is imperative that appropriate lifelong monitoring be undertaken based upon the underlying risk (Table 1). For clinical providers caring for this unique population of children and adults, there are several review articles and guidelines that offer risk-based recommendations for the identification of and screening for thyroid disease in childhood cancer survivors [1, 121-125]. …”

Section: Screening and Managementmentioning

confidence: 99%

See 2 more Smart Citations

Thyroid Sequelae of Pediatric Cancer Therapy

Waguespack

2018

Horm Res Paediatr

View full text Add to dashboard Cite

The hypothalamic-pituitary-thyroid axis is a common site of unintended, acquired disease either during or after the treatment of cancer. Children treated with external radiation therapy are at the highest risk for developing a thyroid-related late effect, but thyroid dysfunction and second primary thyroid neoplasms can also occur after treatment with radiopharmaceutical agents such as ¹³¹I-metaiodobenzylguanidine. Increasingly recognized is the development of early thyroid dysfunction as an off-target consequence of the more novel cancer therapeutics such as the tyrosine kinase inhibitors and immune checkpoint inhibitors. Thyroid sequelae resulting from irradiation may manifest only after years to decades of follow-up, and their resultant clinical symptoms may be indolent and non-specific. Therefore, lifelong monitoring of the childhood cancer survivor at risk for thyroid disease is paramount. In this comprehensive review, the myriad thyroid adverse effects resulting from pediatric cancer treatment are discussed and an overview of screening and treatment of these thyroid sequelae provided.

show abstract

Section: Screening and Managementmentioning

confidence: 99%

Section: Screening and Managementmentioning

confidence: 99%

Section: Screening and Managementmentioning

confidence: 99%

See 1 more Smart Citation

Thyroid Sequelae of Pediatric Cancer Therapy

Waguespack

2018

Horm Res Paediatr

View full text Add to dashboard Cite

show abstract

“…AYA patients followed at a community cancer center or rural cancer clinic without a formal survivorship care program or by providers who are unaware of these guidelines may miss important late effects surveillance recommendations from the NCCN and COG. It is critical for the future health of AYAs that harmonization and dissemination of these guidelines continue among all medical providers, including oncologists and PCPs …”

Section: Introductionmentioning

confidence: 99%

“…Progress has been made with harmonization of survivorship guidelines through the work of the International Guideline Harmonization Group. They have completed new guideline papers on issues that impact AYAs, such as cardiomyopathy screening, gonadotoxicity, and thyroid cancer surveillance among others …”

Section: Introductionmentioning

confidence: 99%

Future health of AYA survivors

Burkart

Sanford

Dinner

et al. 2018

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Adolescent and young adult (AYA) oncology patients (ages 15–39) have been identified as a group with healthcare disparities including gaps and challenges in diagnosis, access to care, research, clinical trial participation, and cure rates. Like other patient groups with cancer or other chronic illnesses, disparities can lead to poor future health and outcomes, which is a well‐recognized concern within the AYA population. Cancer is the leading disease‐related cause of death in this age range. Numerous interested groups including the National Cancer Institute have met to address the research and cancer care needs of AYAs. This review highlights how these gaps in care during and after treatment can affect future health of this population of patients. Access to care, models of survivorship care, and lack of provider education are discussed. Survivorship care and use of guidelines, and promotion of psychosocial support and health behaviors during treatment and beyond are essential to optimizing future health of AYA patients.

show abstract

Incidence of and Risk Factors for Histologically Confirmed Solid Benign Tumors Among Long-term Survivors of Childhood Cancer

et al. 2019

View full text Add to dashboard Cite

for the DCOG-LATER Study Group IMPORTANCE Survivors of childhood cancer (CCSs) face risk of developing subsequent tumors. Solid benign tumors may be cancer precursors; benign tumors and cancers may share etiologic factors. However, comprehensive data on the risk for solid benign tumors are lacking. OBJECTIVE To quantify the incidence of and treatment-related risk factors for histologically confirmed solid nonskin benign tumors among CCSs. DESIGN, SETTING, AND PARTICIPANTS This record linkage study involves the Dutch Childhood Oncology Group-Long-Term Effects After Childhood Cancer (DCOG-LATER) cohort of 6165 individuals diagnosed with childhood cancer at younger than 18 years from January 1, 1963, through December 31, 2001, in 7 Dutch pediatric centers and who survived at least 5 years after the diagnosis. Study groups eligible for record linkage from 1990 onward included 5843 CCSs (94.8%) and 883 siblings. Benign tumors were identified from the population-based Dutch histopathology and cytopathology registry (PALGA). Follow-up was completed on May

show abstract

Balancing the benefits and harms of thyroid cancer surveillance in survivors of Childhood, adolescent and young adult cancer: Recommendations from the international Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCareSurFup Consortium

Cited by 107 publications

References 84 publications

Thyroid Sequelae of Pediatric Cancer Therapy

Thyroid Sequelae of Pediatric Cancer Therapy

Future health of AYA survivors

Incidence of and Risk Factors for Histologically Confirmed Solid Benign Tumors Among Long-term Survivors of Childhood Cancer

Contact Info

Product

Resources

About